LifeSci Capital analyst Kate Dellorusso has maintained their neutral stance on MREO stock, giving a Hold rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Kate Dellorusso has given his Hold rating due to a combination of factors tied to both clinical uncertainty and financial positioning. The recent Phase 3 trials of setrusumab in osteogenesis imperfecta failed to achieve their primary fracture-rate endpoint, and while younger patients showed encouraging signals on vertebral fractures and pain, the ultimate regulatory and commercial path for the program remains unclear, leading the team to adopt a wait-and-see stance as additional analyses continue.
Mereo’s broader pipeline offers potential upside, including efforts to secure a partner for alvelestat and the planned Phase 2 trial of vanticumab by āshibio, but these value drivers are still in early or partnered stages and carry execution risk. At the same time, the company’s cash balance, reduced operating expenses, and runway into mid-2027 provide some support, yet not enough de-risking to warrant a more constructive view, so the risk‑reward profile appears balanced and supports maintaining a Market Perform (Hold) rating.
According to TipRanks, Dellorusso is an analyst with an average return of -27.8% and a 10.00% success rate. Dellorusso covers the Healthcare sector, focusing on stocks such as Upstream Bio, Inc., Soleno Therapeutics, and Crinetics Pharmaceuticals.
In another report released today, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $0.34 price target.